We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Paying Up to $1 Billion for GSK’s Remaining Rights to Arzerra
Novartis Paying Up to $1 Billion for GSK’s Remaining Rights to Arzerra
Novartis has agreed to pay up to $1 billion for the rights to autoimmune indications for GlaxoSmithKline’s Arzerra, including multiple sclerosis, following an earlier deal for the drug’s oncology indications.